MiMedx Group NASDAQ: MDXG is counting on growth in its surgical business and its pending acquisition of Sanara MedTech to help offset a difficult year for its wound care franchise, Chief Financial Officer Doug Rice said at the Canaccord Genuity MedTech and Diagnostics Conference.
Rice said the regenerative medicine company generated $62 million in third-quarter net sales, with roughly two-thirds coming from surgical products. The surgical franchise grew 9% by revenue and at a mid-teens rate by volume year over year, he said.
The company returned to positive adjusted EBITDA and free cash flow in the quarter after reducing its infrastructure earlier in the year, Rice said. MiMedx ended the third quarter with $121 million in cash and no debt, and reported a gross margin of 80%.
Sanara Deal Would Expand Surgical Business
MiMedx announced its planned acquisition of Sanara MedTech alongside its second-quarter results in late July. Rice said Sanara’s business is focused entirely on operating rooms and generates more than $100 million in annual revenue.
Rice said Sanara would add products in areas where MiMedx does not currently operate, including no-rinse irrigation and bone fixation, and provide access to a network of several hundred third-party agents. He estimated the acquisition would open more than $4 billion in additional addressable markets.
In the first year after combining, MiMedx expects to be a roughly $400 million revenue company with more than 20% adjusted EBITDA margins, Rice said. The combined surgical businesses would account for about three-quarters of revenue, he said.
Rice said the company had obtained the necessary approvals for the transaction except for that of the Federal Trade Commission. MiMedx is working with the agency through its second request for information and aims to complete the acquisition as quickly as possible, he said.
Wound Care Adjusts to Reimbursement Changes
Rice said Medicare reimbursement changes that took effect on Jan. 1 significantly reduced spending in the wound care industry and contributed to a challenging year for MiMedx’s mature wound franchise. He said the measures would remain in place in 2027 under the Medicare physician fee schedule and outpatient prospective payment system.
In response to a question, Rice said MiMedx reorganized earlier this year to align with the changing market. The new reimbursement environment is encouraging patients to move into wound care centers, he said, adding that the company continued to see year-over-year volume growth in that setting.
Rice said recovery in the wound market has been sluggish, but described the third quarter as an inflection point because of improving margins and adjusted EBITDA.
Surgical Products and Research
MiMedx’s surgical business generated $40 million in third-quarter revenue, Rice said. The company has two 510(k) submissions for surgical products pending with the Food and Drug Administration.
Rice also cited published data on MiMedx’s AMNIOFIX grafts in gastrointestinal surgery. He said patients who received the grafts had roughly half the rate of anastomotic leaks and a nearly equivalent reduction in 30-day hospital readmissions.
Separately, Rice noted a favorable court ruling involving the surgical product AXIOFILL and a structured $25 million settlement with a wound care competitor related to intellectual property infringement allegations.
About MiMedx Group (NASDAQ:MDXG)
MiMedx Group is a healthcare company that develops and markets biologic products made from donated human placental tissue. Its offerings include amniotic membrane and umbilical cord allografts for use in wound care and surgical procedures. The company's products include EpiFix, used in the management of certain chronic wounds, and other tissue-based products for wound and surgical applications. MiMedx uses its proprietary PURION processing method to prepare donated tissue for clinical use. Founded in 2008 and headquartered in Marietta, Georgia, MiMedx primarily serves healthcare providers in the United States, with sales in select international markets.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MiMedx Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.
While MiMedx Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.